RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes
ABSTRACT Adeno-associated virus (AAV)-based gene therapy could be facilitated by the development of molecular switches to control the magnitude and timing of expression of therapeutic transgenes. RNA interference (RNAi)-based approaches hold unique potential as a clinically proven modality to pharmacologically regulate AAV gene dosage in a sequence-specific manner. We present a generalizable RNAi-based rheostat wherein AAV transgene expression is silenced using the clinically validated modality of chemically modified short interfering RNA (siRNA) conjugates or vectorized co-expression of short hairpin RNA (shRNA). For transgene induction, we employ REVERSIR technology, a synthetic high-affinity oligonucleotide complementary to the siRNA or shRNA guide strand to reverse RNAi activity and rapidly recover transgene expression. For potential clinical development, we report potent and specific siRNA sequences that may allow selective regulation of transgenes while minimizing unintended off-target effects. Our results establish a conceptual framework for RNAi-based regulatory switches with potential for infrequent dosing in clinical settings to dynamically modulate expression of virally-delivered gene therapies..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Subramanian, Megha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.09.30.510386 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI037445502 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI037445502 | ||
| 003 | DE-627 | ||
| 005 | 20240424105018.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221003s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.09.30.510386 |2 doi | |
| 035 | |a (DE-627)XBI037445502 | ||
| 035 | |a (biorXiv)10.1101/2022.09.30.510386 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Subramanian, Megha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Adeno-associated virus (AAV)-based gene therapy could be facilitated by the development of molecular switches to control the magnitude and timing of expression of therapeutic transgenes. RNA interference (RNAi)-based approaches hold unique potential as a clinically proven modality to pharmacologically regulate AAV gene dosage in a sequence-specific manner. We present a generalizable RNAi-based rheostat wherein AAV transgene expression is silenced using the clinically validated modality of chemically modified short interfering RNA (siRNA) conjugates or vectorized co-expression of short hairpin RNA (shRNA). For transgene induction, we employ REVERSIR technology, a synthetic high-affinity oligonucleotide complementary to the siRNA or shRNA guide strand to reverse RNAi activity and rapidly recover transgene expression. For potential clinical development, we report potent and specific siRNA sequences that may allow selective regulation of transgenes while minimizing unintended off-target effects. Our results establish a conceptual framework for RNAi-based regulatory switches with potential for infrequent dosing in clinical settings to dynamically modulate expression of virally-delivered gene therapies. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a McIninch, James |e verfasserin |4 aut | |
| 700 | 1 | |a Zlatev, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Schlegel, Mark K. |e verfasserin |4 aut | |
| 700 | 1 | |a Kaittanis, Charalambos |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Tuyen |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Saket |e verfasserin |4 aut | |
| 700 | 1 | |a Racie, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarado, Martha Arbaiza |e verfasserin |4 aut | |
| 700 | 1 | |a Wassarman, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Collins, Thomas S. |e verfasserin |4 aut | |
| 700 | 1 | |a Chickering, Tyler |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Christopher R. |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Karyn |e verfasserin |4 aut | |
| 700 | 1 | |a Castoreno, Adam B. |e verfasserin |4 aut | |
| 700 | 1 | |a Shulga-Morskaya, Svetlana |e verfasserin |4 aut | |
| 700 | 1 | |a Stamenova, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Buckowing, Kira |e verfasserin |4 aut | |
| 700 | 1 | |a Berman, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Barry, Joseph D. |e verfasserin |4 aut | |
| 700 | 1 | |a Bisbe, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Maier, Martin A. |e verfasserin |4 aut | |
| 700 | 1 | |a Fitzgerald, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Jadhav, Vasant |e verfasserin |0 (orcid)0000-0002-6666-0250 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41467-023-37774-5 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.09.30.510386 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||